MARKET

ATXI

ATXI

Avenue
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.21
+0.31
+6.33%
Opening 13:08 02/24 EST
OPEN
4.980
PREV CLOSE
4.900
HIGH
5.26
LOW
4.980
VOLUME
21.86K
TURNOVER
--
52 WEEK HIGH
12.34
52 WEEK LOW
2.850
MARKET CAP
87.26M
P/E (TTM)
-8.9534
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SOS, WPG, CAN and BLUE among midday movers
Gainers: Luokung Technology (LKCO) +112%.Kubient (KBNT) +63%.SOS (SOS) +58%.Torchlight Energy Resources (TRCH) +54%.Protective Insurance (PTVCB) +53%.500.com (WBAI) +45%.ALJ Regional (ALJJ) +45%.Urban Tea (MYT) +44%.Canaan (CAN) +36%.Applied Genetic Techno...
Seekingalpha · 02/16 17:37
8-K: AVENUE THERAPEUTICS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/16 16:52
H.C. Wainwright Sticks to Their Hold Rating for Avenue Therapeutics (ATXI)
In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Avenue Therapeutics (ATXI), with a price target of $6.00. The
SmarterAnalyst · 02/16 16:36
BRIEF-Avenue Therapeutics Inc - On February 12, Resubmitted Its NDA To FDA For IV Tramadol
reuters.com · 02/16 14:24
Costochondritis Market 2023: Opportunities, New Developments, Competitive Landscape
Jan 20, 2021 (Heraldkeepers) -- Costochondritis is the most common rib inflammatory disease. It is a condition when there is a temporary chest pain....
Heraldkeepers · 01/20 12:41
How Much Of Avenue Therapeutics, Inc. (NASDAQ:ATXI) Do Institutions Own?
A look at the shareholders of Avenue Therapeutics, Inc. ( NASDAQ:ATXI ) can tell us which group is most powerful...
Simply Wall St. · 01/12 04:32
How Much Of Avenue Therapeutics, Inc. (NASDAQ:ATXI) Do Institutions Own?
A look at the shareholders of Avenue Therapeutics, Inc. ( NASDAQ:ATXI ) can tell us which group is most powerful...
Simply Wall St. · 01/12 04:32
How Much Of Avenue Therapeutics, Inc. (NASDAQ:ATXI) Do Institutions Own?
Simply Wall St. · 01/12 04:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATXI. Analyze the recent business situations of Avenue through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATXI stock price target is 9.00 with a high estimate of 12.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 52
Institutional Holdings: 2.09M
% Owned: 12.45%
Shares Outstanding: 16.75M
TypeInstitutionsShares
Increased
14
398.51K
New
13
-1.10M
Decreased
6
5.51K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.30%
Pharmaceuticals & Medical Research
+1.34%
Key Executives
Chairman/Director
Lindsay Rosenwald
President/Chief Executive Officer/Director
Lucy Lu
Chief Financial Officer/Secretary
Joseph Vazzano
Director
Jaideep Gogtay
Director
Garrett Ingram
Independent Director
Neil Herskowitz
Independent Director
Jay Kranzler
  • Dividends
  • Splits
  • Insider Activity
No Data
About ATXI
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The Company’s product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Its Oral tramadol is marketed in the United States for moderate to moderately severe pain in adults. Its Parenteral tramadol formulations include IV, intramuscular (IM), and subcutaneous (SC) formulations. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States.

Webull offers kinds of Avenue Therapeutics Inc stock information, including NASDAQ:ATXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATXI stock methods without spending real money on the virtual paper trading platform.